Total Payments
$60,308
2024 Payments
$6,781
Companies
66
Transactions
388
Medicare Patients
19,886
Medicare Billing
$3.8M
Payment Breakdown by Category
Other$32,792 (54.4%)
Consulting$18,590 (30.8%)
Food & Beverage$8,347 (13.8%)
Education$495.13 (0.8%)
Travel$84.92 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $29,435 | 10 | 48.8% |
| Consulting Fee | $18,590 | 20 | 30.8% |
| Food and Beverage | $8,347 | 321 | 13.8% |
| Honoraria | $2,425 | 2 | 4.0% |
| Long term medical supply or device loan | $931.52 | 10 | 1.5% |
| Education | $495.13 | 22 | 0.8% |
| Travel and Lodging | $84.92 | 3 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $27,116 | 45 | $0 (2024) |
| Millennium Pharmaceuticals, Inc. | $5,663 | 5 | $0 (2017) |
| Eli Lilly and Company | $4,375 | 1 | $0 (2022) |
| GENZYME CORPORATION | $4,225 | 20 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $3,807 | 4 | $0 (2023) |
| Karyopharm Therapeutics Inc. | $2,473 | 8 | $0 (2023) |
| BeiGene USA, Inc. | $1,950 | 1 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $1,440 | 38 | $0 (2024) |
| Puma Biotechnology, Inc. | $1,150 | 3 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $1,110 | 17 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $6,781 | 47 | GENZYME CORPORATION ($3,562) |
| 2023 | $3,574 | 94 | Janssen Scientific Affairs, LLC ($1,090) |
| 2022 | $7,182 | 71 | Eli Lilly and Company ($4,375) |
| 2021 | $1,794 | 37 | AstraZeneca Pharmaceuticals LP ($593.02) |
| 2020 | $2,880 | 20 | Karyopharm Therapeutics Inc. ($2,282) |
| 2019 | $12,444 | 46 | E.R. Squibb & Sons, L.L.C. ($8,943) |
| 2018 | $7,497 | 29 | E.R. Squibb & Sons, L.L.C. ($5,889) |
| 2017 | $18,156 | 44 | E.R. Squibb & Sons, L.L.C. ($11,652) |
All Payment Transactions
388 individual payment records from CMS Open Payments — Page 5 of 16
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/08/2023 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $30.34 | General |
| Category: Oncology | ||||||
| 06/06/2023 | Seagen Inc. | TUKYSA (Drug) | Food and Beverage | In-kind items and services | $28.63 | General |
| Category: Oncology | ||||||
| 06/06/2023 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $22.43 | General |
| Category: Oncology | ||||||
| 05/31/2023 | Genentech USA, Inc. | Tecentriq (Biological) | Food and Beverage | In-kind items and services | $24.06 | General |
| Category: BioOncology | ||||||
| 05/30/2023 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $19.27 | General |
| Category: ONC | ||||||
| 05/23/2023 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $27.53 | General |
| Category: Oncology | ||||||
| 05/18/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $29.29 | General |
| Category: ONCOLOGY | ||||||
| 05/16/2023 | PFIZER INC. | IBRANCE (Drug) | Food and Beverage | In-kind items and services | $29.82 | General |
| Category: ONCOLOGY | ||||||
| 05/09/2023 | Janssen Scientific Affairs, LLC | — | Consulting Fee | Cash or cash equivalent | $1,090.00 | General |
| 05/09/2023 | AVEO Pharmaceuticals, Inc. | FOTIVDA (Drug) | Food and Beverage | In-kind items and services | $33.69 | General |
| Category: Oncology | ||||||
| 05/09/2023 | Astellas Pharma US Inc | Xospata (Drug) | Food and Beverage | In-kind items and services | $30.98 | General |
| Category: Oncology | ||||||
| 05/08/2023 | Seagen Inc. | TUKYSA (Drug) | Food and Beverage | In-kind items and services | $15.78 | General |
| Category: Oncology | ||||||
| 05/04/2023 | Novartis Pharmaceuticals Corporation | TABRECTA (Drug) | Food and Beverage | In-kind items and services | $24.97 | General |
| Category: Oncology | ||||||
| 05/03/2023 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $24.31 | General |
| Category: Oncology | ||||||
| 04/26/2023 | Seagen Inc. | ADCETRIS (Biological) | Food and Beverage | In-kind items and services | $25.31 | General |
| Category: Oncology | ||||||
| 04/25/2023 | Octapharma USA, Inc. | PANZYGA (Biological) | Food and Beverage | In-kind items and services | $20.57 | General |
| Category: IMMUNOLOGY | ||||||
| 04/20/2023 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $29.78 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 04/20/2023 | Bayer Healthcare Pharmaceuticals Inc. | Stivarga (Drug) | Food and Beverage | In-kind items and services | $17.24 | General |
| Category: Oncology | ||||||
| 04/18/2023 | Celgene Corporation | OPDUALAG (Drug) | Food and Beverage | Cash or cash equivalent | $29.09 | General |
| Category: Oncology | ||||||
| 04/12/2023 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $32.37 | General |
| Category: Oncology | ||||||
| 04/12/2023 | Novartis Pharmaceuticals Corporation | TABRECTA (Drug) | Food and Beverage | In-kind items and services | $25.19 | General |
| Category: Oncology | ||||||
| 03/28/2023 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $25.84 | General |
| Category: Oncology | ||||||
| 03/24/2023 | Lilly USA, LLC | VERZENIO (Drug) | Food and Beverage | In-kind items and services | $29.95 | General |
| Category: Oncology | ||||||
| 03/22/2023 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $25.30 | General |
| Category: Hematology/Oncology | ||||||
| 03/22/2023 | Puma Biotechnology, Inc. | — | Food and Beverage | In-kind items and services | $24.55 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 53 | 5,613 | 49,742 | $1.9M | $754,995 |
| 2022 | 51 | 5,301 | 53,441 | $2.9M | $1.2M |
| 2021 | 45 | 4,756 | 34,834 | $2.6M | $1.1M |
| 2020 | 43 | 4,216 | 27,852 | $2.0M | $791,618 |
Total Patients
19,886
Total Services
165,869
Medicare Billing
$3.8M
Procedure Codes
192
All Medicare Procedures & Services
192 procedure records from CMS Medicare Utilization — Page 1 of 8
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 467 | 1,850 | $524,282 | $198,695 | 37.9% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 33 | 6,257 | $278,374 | $113,665 | 40.8% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 51 | 445 | $144,096 | $55,052 | 38.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 122 | 427 | $92,126 | $43,360 | 47.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 125 | 272 | $108,354 | $42,323 | 39.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 177 | 331 | $66,597 | $25,413 | 38.2% |
| J1437 | Injection, ferric derisomaltose, 10 mg | Office | 2023 | 11 | 1,400 | $63,602 | $22,321 | 35.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 122 | 147 | $61,409 | $21,712 | 35.4% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 504 | 2,265 | $34,390 | $17,223 | 50.1% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 14 | 244 | $43,795 | $16,743 | 38.2% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 463 | 1,614 | $33,982 | $16,697 | 49.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 77 | 77 | $37,210 | $14,490 | 38.9% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 33 | 520 | $36,267 | $13,968 | 38.5% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 14 | 95 | $32,041 | $11,361 | 35.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 80 | 80 | $29,475 | $11,271 | 38.2% |
| 83735 | Magnesium level | Office | 2023 | 428 | 1,635 | $21,830 | $10,737 | 49.2% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 18 | 55 | $25,458 | $9,950 | 39.1% |
| 82784 | Gammaglobulin (immune system protein) measurement | Office | 2023 | 112 | 946 | $17,596 | $8,621 | 49.0% |
| 86140 | Measurement c-reactive protein for detection of infection or inflammation | Office | 2023 | 435 | 1,598 | $16,493 | $8,110 | 49.2% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 44 | 121 | $19,312 | $7,229 | 37.4% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2023 | 19 | 18,360 | $20,196 | $7,192 | 35.6% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 54 | 105 | $16,000 | $7,123 | 44.5% |
| 82728 | Ferritin (blood protein) level | Office | 2023 | 252 | 534 | $14,531 | $7,122 | 49.0% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 421 | 1,124 | $6,744 | $6,609 | 98.0% |
| 82378 | Carcinoembryonic antigen (cea) protein level | Office | 2023 | 59 | 318 | $12,003 | $5,908 | 49.2% |
About Dr. Ashkan Lashkari, MD
Dr. Ashkan Lashkari, MD is a Hematology & Oncology healthcare provider based in West Hills, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/17/2007. The National Provider Identifier (NPI) number assigned to this provider is 1528284627.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ashkan Lashkari, MD has received a total of $60,308 in payments from pharmaceutical and medical device companies, with $6,781 received in 2024. These payments were reported across 388 transactions from 66 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($29,435).
As a Medicare-enrolled provider, Lashkari has provided services to 19,886 Medicare beneficiaries, totaling 165,869 services with total Medicare billing of $3.8M. Data is available for 4 years (2020–2023), covering 192 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location West Hills, CA
- Active Since 04/17/2007
- Last Updated 09/30/2010
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1528284627
Products in Payments
- OPDIVO (Biological) $20,661
- EMPLICITI (Biological) $5,848
- NINLARO (Drug) $5,663
- SARCLISA (Biological) $3,965
- IMBRUVICA (Drug) $2,890
- XPOVIO (Drug) $2,473
- BRUKINSA (Drug) $1,950
- Nerlynx (Drug) $1,125
- KISQALI (Drug) $895.88
- KEYTRUDA (Biological) $420.40
- ADCETRIS (Biological) $260.25
- VERZENIO (Drug) $241.19
- ELITEK (Biological) $225.54
- TAGRISSO (Drug) $225.00
- IBRANCE (Drug) $196.05
- BESREMI (Drug) $181.99
- LIBTAYO (Biological) $172.44
- CYRAMZA (Drug) $172.26
- ENHERTU (Biological) $164.06
- TABRECTA (Drug) $152.02
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in West Hills
Mr. Christopher Ho, M.d, M.D
Hematology & Oncology — Payments: $79,475
Hematology & Oncology $79,475
Michael Benjamin, M.d, M.D
Hematology & Oncology — Payments: $21,070
Hematology & Oncology $21,070
Dr. Omid Shaye, M.d, M.D
Hematology & Oncology — Payments: $12,978
Hematology & Oncology $12,978
Bruce Zietz, M.d, M.D
Hematology & Oncology
Hematology & Oncology